Candida Infection
Conditions
Brief summary
Bloodstream infections due to Candida spp remain a serious medical challenge because of their high incidence and poor outcome. Diagnosis and monitoring of patients are still problematic, hindering efficient clinical management of the disease. The invastigators propose here to perform a retrospective study in a clinically well-characterized candidemic patient, with the goal of recognizing host immunological factors and virulence-associated fungal molecules relevant in the onset and evolution of infection. The researchers' ultimate goal is to identify new diagnostic and/or prognostic benchmarks useful in clinical settings. By combining serologic and immunologic expertise with clinical expertise, the research team has real potential to generate new markers of host pathogenesis and immune response in candidemia and to inform prospective clinical trials to control this terrible disease
Interventions
DIAGNOSTIC_TESTcollection of blood samples
For each patient, a serum sample collected at the time when candidemia is suspected (time of execution of blood cultures) will be examined. For patients with candidemia, all serum samples taken during infection follow-up will also be examined.
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* patients hospitalized * one or more positive blood cultures for Candida spp, * positive beta-glucanemia * the presence of at least one clinical symptom of infection will be considered cases of candidemia.
Exclusion criteria
* age less than 18 years * state of immunosuppression * incompleteness of clinical data * unavailability of serum samples in sufficient quantities for analysis and in good condition.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| levels of antibodies | 1 year | i) presence and levels of antibodies directed towards beta-glucans and Candida virulence proteins. ii) presence and levels of circulating Candida virulence proteins. iii) presence and levels of soluble mediators of innate immunity and inflammation No genetic analysis will be performed. |
Countries
Italy
Outcome results
None listed